Recruiting
Phase 1
Phase 2

IMP1734

Sponsor:

Eikon Therapeutics

Code:

NCT06253130

Conditions

Advanced Solid Tumor

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

IMP1734

Study Details

Brief summary:

This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

Conditions

Advanced Solid Tumor

Study ID

NCT06253130

Start date

Dec 11, 2023

Status verified date

Jun, 2026

Completion date

Dec 1, 2027

Anticipated

Primary completion date

Jun 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Key Inclusion Criteria

  • Breast cancer; must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting, must have received hormonal therapy if HR+,
  • HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemotherapy for advanced disease
  • mCRPC with ongoing ADT, must have received NHA and up to 1 prior line of taxane chemotherapy
  • Age ≥ 18 years at the time of informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  • Adequate organ function
  • Life expectancy ≥ 12 weeks
  • Should have evaluable disease as defined by RECIST1.1 and/or CA125 or PSA
  • Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception from study entry up to 6 months after the last dose of IMP1734
  • deleterious or suspected deleterious germline or somatic mutations of select HRR genes
  • up to 1 prior line of PARP inhibitor containing treatment

Key Exclusion Criteria:

  • Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of IMP1734
  • Have received prior PARP1 selective inhibitors
  • Mean resting QTcF > 470 ms or QTcF < 340 ms
  • Active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Infections

\- An active hepatitis B/C infection
  • Any known predisposition to bleeding
  • Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability

Study Design

Enrollment

156 participants

Anticipated

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Cohort 1

IMP1734 monotherapy; oral tablet(s) daily (except for the single-dose period). The maximum trial duration is 3 years after the last participant's first treatment in the trial.

Interventions

IMP1734

PARP1 selective inhibitor

Primary outcome measure

  • Number of subjects with adverse events, treatment emergent adverse events or serious adverse events [ Time Frame: Consent to 30 + 7 days post last dose of IMP1734 ]
  • Maxim Tolerated Dose or Recommended Dose for Expansion [ Time Frame: DLT period is from the first dose of the study drug until the last day of the first cycle ]

Central Contacts and Locations

Central contacts

Nicola Lynch

212-540-4923parpitrial@eikontx.com

Locations

The University of Arizona Cancer Center

Recruiting

Tucson, Arizona, United States, 85719

Contacts

Spencer Study Coordinator

520-694-4374spencerwilliams@arizona.edu

Principal Investigator:

Alejandro Recio-Boiles, MD

University of Arkansas Winthrop P. Rockefeller Cancer Institute

Recruiting

Little Rock, Arkansas, United States, 72205

Contacts

Maroof Study Coordinator

501-686-8274mkzafar@uams.edu

Principal Investigator:

Michael Birrer, MD

Sarah Cannon Research Institute Health One

Recruiting

Denver, Colorado, United States, 80218

Contacts

Hannah Study Nurse

720-754-2610Hannah.Asbell@SarahCannon.com

Principal Investigator:

Gerald Falchook, MD

Smilow Cancer Hospital at Yale New Haven

Recruiting

New Haven, Connecticut, United States, 06511

Contacts

Sarah Reinwald

203-314-7175sarah.reinwald@yale.edu

Principal Investigator:

Patricia LoRusso, MD

Advent Health Research Institute

Recruiting

Celebration, Florida, United States, 34747

Contacts

Jamayra Study Coordinator

jamayra.espada@adventhealth.com

Principal Investigator:

Guru Sonpavde, MD

Sylvester Comprehensive Cancer Center

Recruiting

Miami, Florida, United States, 33136

Contacts

Lauren Study Coordinator

305-243-8237laurenwalsh@med.miami.edu

Principal Investigator:

Frances Valdes-Albini, MD

University of Michigan Rogel Cancer Center

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Myron Study Coordinator

734-998-4415mhepner@med.umich.edu

Principal Investigator:

Aki Morikawa, MD

Karmanos Cancer Institute

Recruiting

Detroit, Michigan, United States, 48201

Contacts

Brenda Research Nurse

313-576-8408kramerb@karmanos.org

Principal Investigator:

Yusra Shao, MD

Henry Ford Health

Recruiting

Detroit, Michigan, United States, 48202

Contacts

Andrew Study Coordinator

313-439-0182aanasto1@HFHS.ORG

Principal Investigator:

Amy Weise, MD

University of Minnesota-Clinical Research Unit

Recruiting

Minneapolis, Minnesota, United States, 55455

Contacts

Elizabeth Study Coordinator

612-626-1358molle086@umn.edu

Principal Investigator:

Heather Beckwith, MD

Lifespan Cancer Institute

Recruiting

Providence, Rhode Island, United States, 02903

Contacts

Sopha Research Nurse

401.444.8946sdionson@brownhealth.org

Principal Investigator:

Benedito Carneiro, MD

Medical University of South Carolina (MUSC) - Hollings CC

Recruiting

Charleston, South Carolina, United States, 29425

Contacts

Abigail Study Coordinator

abd300@musc.edu

Principal Investigator:

Brian Orr, MD

West Cancer Center & Research Institute

Recruiting

Germantown, Tennessee, United States, 38138

Contacts

Rebecca Study Coordinator

rblair@westclinic.com

Principal Investigator:

Daniel Vaena, MD

Sarah Cannon Research Institue Oncology

Recruiting

Nashville, Tennessee, United States, 37203

Contacts

Emma Study Coordinator

(615) 917 - 9153Emma.Brennan@scri.com

Principal Investigator:

Benjamin Garmezy, MD

Cross Cancer Institute

Recruiting

Edmonton, Alberta, Canada, T6G 1Z2

Contacts

Noor Study Coordinator

noor.khattak@albertahealthservices.ca

Principal Investigator:

Quincy Chu, MD

Sunnybrook Research Institute

Recruiting

Toronto, Ontario, Canada, M4N 3M5

Contacts

Donna Study Coordinator

donna.morgan1@sunnybrook.ca

Principal Investigator:

Rossanna Pezo, MD

Princess Margaret Cancer Centre-University Health Network

Recruiting

Toronto, Ontario, Canada, M5G 2M9

Contacts

Riya Study Coordinator

riya.agrawal@uhn.ca

Principal Investigator:

Amit Oza, MD

More Information

Sponsor

Eikon Therapeutics

Last update posted

Jun 15, 2026

Last verified

Jun, 2026

Keywords

  • EIK1003
  • EIK1003-001
  • IMP1734

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Eikon Therapeutics on 2026-06-15.